By proceeding, you agree to our Terms of Use and Privacy Policy.
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Attend panel discussions and sessions about ligases.
Learn cutting-edge information about New E3 Ligases & E3 Ligands, new technologies to find Novel E3 Ligases.
Listen to leaders from Pfizer, A-Alpha Bio, Amgen, and Nurix Therapeutics about the future potential of E3 Ligases.
Hear from leading pharma specialists, scientists, and chief scientific officers through presentations, sessions and panel discussions.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.